Blog
Is RTX Strengthening Its Position in the Electronic Warfare Market?
RTX Corporation RTX continues to strengthen its position in the electronic warfare (EW) market through its portfolio of advanced electronic attack, sensing and mission systems that support modern
NOV Stock Rallies 49% in a Year: Time to Buy or Move On?
Shares of NOV Inc. NOV climbed 49.5% in the past year compared with the Mechanical and Equipment Oil and Gas sub-industry and the broader oil and energy sector's rise of 62% and 25.3%, respectively
How Much Upside is Left in Allegiant Travel (ALGT)? Wall Street Analysts Think 25.67%
Shares of Allegiant Travel (ALGT) have gained 12.2% over the past four weeks to close the last trading session at $106.89, but there could still be a solid upside left in the stock if short-term
Wall Street Analysts Predict a 94.13% Upside in FTC Solar (FTCI): Here's What You Should Know
FTC Solar (FTCI) closed the last trading session at $5.28, gaining 17.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Believe Fox (FOXA) Could Rally 27.67%: Here's is How to Trade
Shares of Fox (FOXA) have gained 2.1% over the past four weeks to close the last trading session at $55.9, but there could still be a solid upside left in the stock if short-term price targets of
Can Fox (FOX) Climb 38.77% to Reach the Level Wall Street Analysts Expect?
Fox Corporation (FOX) closed the last trading session at $50.22, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet
Definium Therapeutics, Inc. (DFTX) closed the last trading session at $43.65, gaining 83.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price
Wall Street Analysts Think Accelerant Holdings (ARX) Could Surge 39.43%: Read This Before Placing a Bet
Shares of Accelerant Holdings (ARX) have gained 2.6% over the past four weeks to close the last trading session at $13.34, but there could still be a solid upside left in the stock if short-term
Wall Street Analysts See a 43.91% Upside in ExlService Holdings (EXLS): Can the Stock Really Move This High?
ExlService Holdings (EXLS) closed the last trading session at $28.49, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts Believe JD.com (JD) Could Rally 40.06%: Here's is How to Trade
JD.com, Inc. (JD) closed the last trading session at $28.88, gaining 0.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Believe Coastal Financial (CCB) Could Rally 32%: Here's is How to Trade
Coastal Financial Corporation (CCB) closed the last trading session at $78.6, gaining 10.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price
Wall Street Analysts Believe Oportun Financial (OPRT) Could Rally 55.87%: Here's is How to Trade
Shares of Oportun Financial Corporation (OPRT) have gained 9.6% over the past four weeks to close the last trading session at $5.71, but there could still be a solid upside left in the stock if
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
Shares of BioCryst Pharmaceuticals (BCRX) have gained 9.4% over the past four weeks to close the last trading session at $9.91, but there could still be a solid upside left in the stock if
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade
Shares of Pharvaris N.V. (PHVS) have gained 11.2% over the past four weeks to close the last trading session at $35.07, but there could still be a solid upside left in the stock if short-term price
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
Syndax Pharmaceuticals (SNDX) closed the last trading session at $22.89, gaining 23.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
Wall Street Analysts Believe United (UAL) Could Rally 26.63%: Here's is How to Trade
Shares of United Airlines (UAL) have gained 1% over the past four weeks to close the last trading session at $121.16, but there could still be a solid upside left in the stock if short-term price
Newsmax (NMAX) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Newsmax Inc. (NMAX) could be a good stock pick from a technical perspective. NMAX recently experienced a "golden cross" event, which saw its 50-day simple
BuyWrite ETF (BUYW) Touches Fresh 52-Week High
For investors seeking momentum, Main BuyWrite ETF BUYW is probably on the radar now. The fund just hit a 52-week high and is up 5.1% from its 52-week low price of $13.84 per share.
But are there
How Is KTOS Benefiting From the US Defense Industrial Base Expansion?
Kratos Defense & Security Solutions, Inc. KTOS is investing in manufacturing infrastructure to support higher production volumes rather than relying solely on the development of advanced
Accelerant Advances Fee-Based Model With WoodStar Partnership
Accelerant Holdings ARX, a data-driven risk exchange company, has announced a strategic partnership with the newly formed WoodStar Reciprocal Exchange (WoodStar). WoodStar has secured more than $220
Healthcare ETFs to Buy as JNJ Beats the Market With a 25% YTD Surge
Johnson & Johnson JNJ, a healthcare behemoth with a market cap exceeding $600 billion and a portfolio spanning pharmaceuticals and medical devices, has delivered a stellar year-to-date surge of
Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
Intuitive Surgical ISRG is set to report second-quarter 2026 earnings on July 16. The Zacks Consensus Estimate for sales and earnings is pegged at $2.81 billion and $2.48 per share, respectively
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
Bristol Myers Squibb BMY recently announced that the FDA has accepted its new drug application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with



